FDA Reshapes Drug Testing Approach - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

  • By

  • Kathryn Wighton

  • April 20, 2026

  • 2 min

Share

  • 1

    The FDA is implementing a roadmap to reduce animal testing in drug development by 2025, meeting initial milestones.

  • 2

    Alternative methods, such as in vitro systems and computational modeling, are being advanced to improve drug testing accuracy.

  • 3

    Over 90% of drugs deemed safe in animal studies fail during human trials due to safety or efficacy issues.

  • 4

    The FDA has issued guidance to eliminate nonhuman primate testing and reduce horseshoe crab-derived endotoxin testing.

  • 5

    Collaboration with international regulators and NIH supports the FDA's efforts to improve drug safety predictions and reduce animal use.

Original Source(s)

FDA Reshapes Drug Testing Approach

  • by Kathryn Wighton

  • April 20, 2026

Related Content

Does portal writing style contribute to disparities in clinician response?

Message length, punctuation, and clinician greetings were associated with intended clinician response.

Educators weigh how to use AI without losing critical thinking

Greater productivity is not necessarily indicative of greater knowledge.

10 states that support physician work-life balance

These 10 states have paid family or medical leave programs and health, wellness, peer support, or monitoring resources available to physicians or other health professionals.